293 related articles for article (PubMed ID: 26799697)
21. Essential Thrombocythemia: One-Center Data in a Changing Disease.
Pirciulescu N; Gaman MA; Mihailescu M; Constantin C; Dragomir M; Dobrea C; Costache S; Ursuleac I; Coriu D; Crisan AM
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557000
[TBL] [Abstract][Full Text] [Related]
22. Predictors of survival and cause of death in patients with essential thrombocythemia.
Lekovic D; Gotic M; Sefer D; Mitrovic-Ajtic O; Cokic V; Milic N
Eur J Haematol; 2015 Nov; 95(5):461-6. PubMed ID: 25645731
[TBL] [Abstract][Full Text] [Related]
23. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
Passamonti F; Thiele J; Girodon F; Rumi E; Carobbio A; Gisslinger H; Kvasnicka HM; Ruggeri M; Randi ML; Gangat N; Vannucchi AM; Gianatti A; Gisslinger B; Müllauer L; Rodeghiero F; d'Amore ES; Bertozzi I; Hanson CA; Boveri E; Marino F; Maffioli M; Caramazza D; Antonioli E; Carrai V; Buxhofer-Ausch V; Pascutto C; Cazzola M; Barbui T; Tefferi A
Blood; 2012 Aug; 120(6):1197-201. PubMed ID: 22740446
[TBL] [Abstract][Full Text] [Related]
24. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.
Barbui T; Vannucchi AM; Buxhofer-Ausch V; De Stefano V; Betti S; Rambaldi A; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Gisslinger H; Finazzi G; Carobbio A; Thiele J; Passamonti F; Falcone C; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e369. PubMed ID: 26617062
[No Abstract] [Full Text] [Related]
25. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
Qin Y; Wang X; Zhao C; Wang C; Yang Y
Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
[TBL] [Abstract][Full Text] [Related]
26. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
27. Contribution of cardiovascular risk factors in the thrombotic complications of essential thrombocythaemia: a Hungarian single-institute retrospective analysis.
Pósfai É; Marton I; Kotosz B; Borbényi Z
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(7):1258-63. PubMed ID: 25912587
[TBL] [Abstract][Full Text] [Related]
28. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.
Alvarez-Larrán A; Cuevas B; Velez P; Noya S; Caballero-Navarro G; Ferrer-Marín F; Carbonell S; Pérez-Encinas M; Gómez-Casares MT; Pérez-López R; Magro E; Moretó A; Pastor-Galán I; Angona A; Mata-Vázquez MI; Guerrero-Fernández L; Guerra JM; Carreño-Tarragona G; Fox L; Murillo I; García-Gutiérrez V; Mora E; Stuckey R; Arellano-Rodrigo E; Hernández-Boluda JC; Pereira A
Hemasphere; 2023 Aug; 7(8):e936. PubMed ID: 37476303
[TBL] [Abstract][Full Text] [Related]
29. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
[TBL] [Abstract][Full Text] [Related]
30. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
[TBL] [Abstract][Full Text] [Related]
31. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
[TBL] [Abstract][Full Text] [Related]
32. The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia.
Lekovic D; Gotic M; Milic N; Miljic P; Mitrovic M; Cokic V; Elezovic I
Med Oncol; 2014 Oct; 31(10):231. PubMed ID: 25223529
[TBL] [Abstract][Full Text] [Related]
33. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan.
Baba T; Hashimoto Y; Yasuda H; Araki M; Edahiro Y; Morishita S; Ochiai T; Shirane S; Ando J; Komatsu N
Hematology; 2022 Dec; 27(1):157-166. PubMed ID: 35068369
[TBL] [Abstract][Full Text] [Related]
34. Prediction of major bleeding events in 1381 patients with essential thrombocythemia.
Stuckey R; Ianotto JC; Santoro M; Czyż A; Encinas MMP; Gómez-Casares MT; Pereira MSN; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Sobas MA
Int J Hematol; 2023 Nov; 118(5):589-595. PubMed ID: 37660316
[TBL] [Abstract][Full Text] [Related]
35. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
36. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Andriani A; Latagliata R; Anaclerico B; Spadea A; Rago A; Di Veroli A; Spirito F; Porrini R; De Muro M; Crescenzi Leonetti S; Villivà N; De Gregoris C; Montefusco E; Polverelli N; Santoro C; Breccia M; Cimino G; Majolino I; Mazzucconi MG; Vianelli N; Alimena G; Montanaro M; Palandri F
Am J Hematol; 2016 Mar; 91(3):318-21. PubMed ID: 26748894
[TBL] [Abstract][Full Text] [Related]
37. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
38. Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy.
Aroldi A; Cecchetti C; Colombo A; Cattaneo L; Pioltelli PE; Pogliani EM; Elli EM
Eur J Haematol; 2016 Jun; 96(6):593-601. PubMed ID: 26205460
[TBL] [Abstract][Full Text] [Related]
39. [Correlations of jak2v617f mutation with clinical and laboratory findings in primary thrombocythemia patients].
Xia J; Xu W; Zhang SJ; Sun XM; Duan LM; Li WD; Qiou HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):416-20. PubMed ID: 18426677
[TBL] [Abstract][Full Text] [Related]
40. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
